Health care costs among renal cancer patients using pazopanib and sunitinib.

ABSTRACT:

Background

Pazopanib was noninferior to sunitinib in progression-free survival in a phase III, open-label, randomized clinical trial comparing the efficacy and safety of the 2 drugs for treatment of patients with advanced renal cell carcinoma (RCC). A secondary analysis of this trial conducted on patient-reported health care resource utilization (HCRU) endpoints revealed significantly fewer monthly telephone consultations and emergency department visits among patients treated with pazopanib over the first 6 months of treatment.

Objectives

To (a) compare total costs of HCRU and adverse events (AEs) in patients with advanced RCC receiving first-line pazopanib or sunitinib from the phase III clinical trial and (b) perform a post hoc economic analysis that applied direct medical

SUBMITTER: Hansen RN 

PROVIDER: S-EPMC10398249 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature